查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1929637

猴痘快速檢測套組市場：依檢測技術、樣本類型、通路、應用和最終用戶分類，全球預測（2026-2032年）

Monkeypox Rapid Test Kit Market by Test Technology, Sample Type, Distribution Channel, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年猴痘快速檢測套組市值為 4.3937 億美元，預計到 2026 年將成長至 4.7656 億美元，預計到 2032 年將達到 7.2105 億美元，複合年成長率為 7.33%。

主要市場統計數據
基準年 2025 4.3937億美元
預計年份：2026年 4.7656億美元
預測年份：2032年 7.2105億美元
複合年成長率 (%) 7.33%

一份策略性入門指南，闡述了快速猴痘診斷為何已成為臨床工作流程、公共衛生應變和供應鏈規劃中不可或缺的工具。

快速診斷已從一種小眾的實驗室工具發展成為疫情控制和臨床分診的第一線工具。猴痘病毒高就地檢驗的出現改變了臨床流程，使得病例識別更及時、隔離通訊協定更有效，公共衛生資源的分配也更有效率。本文概述了推動猴痘快速檢測套組需求的營運要務，並將該產品類型置於更廣泛的感染疾病控制框架中。

技術進步、醫療服務分散化和監管要求加強將如何重新定義猴痘快速診斷策略和市場趨勢

由於技術的成熟、診療模式的轉變以及監管要求的不斷變化，快速猴痘診斷領域正經歷著變革性的轉變。首先，曾經針對特定應用場景的照護現場平台，如今已擴展到更廣泛的臨床和社區醫療環境。易用性、穩定性以及對操作人員培訓的精簡已成為至關重要的設計要求。因此，側向流動和微流體平台也在不斷改進，以在保持經濟性和可擴展性的同時，提供更穩定的效能。

2025年關稅引發的供應鏈壓力累積影響以及調整採購、製造和分銷決策的戰略應對措施

2025年推出的新關稅和貿易措施為全球診斷組件和成品快速檢測套組的供應鏈帶來了新的複雜性。傳統上依賴低成本製造地的供應商面臨迫在眉睫的成本壓力，迫使他們重新評估採購、庫存策略和合約條款。許多製造商試圖透過供應商多元化、將關鍵流程外包以及與契約製造重新談判條款來降低風險。

對產品類型、平台技術、臨床應用情境和分銷管道進行詳細的細分分析，並將市場接受度趨勢與商業策略連結起來。

細分市場分析揭示了產品設計、平台選擇、臨床應用環境和分銷管道策略如何相互作用，從而決定猴痘快速診斷試劑的採用管道。按產品類型分類，IgG、IgG/IgM聯合檢測和IgM檢測之間的差異影響著臨床效用。 IgM特異性檢測優先用於早期感染檢測，是急性診斷管道的首選；而IgG和聯合檢測則有助於血清狀態評估和回顧性病例調查。這些功能差異指導著檢測的部署地點和方式，進而影響製造商對分析靈敏度、交叉反應譜和樣本採集時間的關注。

區域醫療保健基礎設施、監管重點和分銷生態系統如何影響快速診斷部署策略（美洲、歐洲/中東/非洲、亞太地區）

區域趨勢反映了美洲、歐洲、中東和非洲以及亞太地區在醫療基礎設施、法規結構和分銷生態系統方面的差異，這些差異使得快速檢測的推廣應用面臨獨特的營運挑戰。在美洲，強大的檢查室網路和完善的供應鏈促成了快速診斷技術融入緊急應變和社區篩檢計畫。然而，遍遠地區醫療資源取得的不便以及報銷管道的差異，要求制定有針對性的分銷策略，同時重視醫院和零售藥局通路。

競爭格局趨勢：臨床檢驗、策略合作和服務整合定義了快速診斷生態系統中的差異化優勢

快速猴痘診斷領域的競爭動態由成熟的體外診斷公司、專業的快速檢測試劑生產商和靈活的新創參與企業共同構成。主要企業憑藉其平台的通用性、良好的監管記錄和強大的分銷網路脫穎而出。那些投資於不同環境的臨床檢驗並能證明批次間性能穩定的公司，更有可能與醫院和中央採購機構建立優先合作關係。

製造商和經銷商的實際優先事項是：將產品設計、彈性供應鏈和證據生成與區域通路策略相協調。

產業領導者應採取協作策略，將產品設計、供應鏈韌性和證據產生結合，以推動產品普及並保持競爭優勢。應優先考慮平台適應性，提供既支援照護現場(POC) 工作流程又支援中心檢查室確認的檢測產品。設計可在臨床和社區環境中使用的檢測產品，可擴大其應用場景，並簡化與不同終端使用者的採購談判。

為了支持報告的結論，我們採用了一種透明、可複製和多方面的研究途徑，結合了相關人員訪談、監管審查和供應鏈情境分析。

本研究整合了定性訪談、文獻綜述以及監管和分銷框架的系統性梳理，以整體情況快速​​診斷技術。主要資訊來源包括對臨床醫生、檢查室主任、醫院採購負責人、社區健康專案經理以及參與診斷商業化的高階主管的結構化訪談。研究結果與監管文件、同行評審的臨床檢驗研究以及已發布的上市後績效總結進行三角驗證，以確保與當前實踐相符。

對診斷、供應鏈和區域趨勢進行簡明扼要的綜合分析，明確了在快速猴痘檢測環境中運作的相關人員的策略要務。

總而言之，目前快速猴痘診斷的特點是檢測日益分散化、平台類型技術差異化以及在貿易壓力下加強供應鏈韌性。不同類型的產品，例如 IgM、IgG 和多重檢測，發揮互補的臨床作用；而平台選擇，例如側向層析、膠體金和微流體系統，則決定了成本、易用性和分析性能之間的權衡。從醫院檢查室到病患自測管道，終端使用者都要求獲得客製化解決方案以及在真實環境中證明其效能的證據。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章 美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

8. 猴痘快速檢測套組市場（依檢測技術分類）

  • 側向流動免疫檢測
    • 視覺評估
    • 領導者
  • 恒溫核酸增幅法
    • 環介導擴增
    • 重組酶聚合酵素擴增
  • 快速聚合酵素鏈鎖反應
    • 基於墨盒的系統
    • 開放系統套件
  • 基於CRISPR的檢測方法
    • Cas12 檢測
    • Cas13 檢測

9. 猴痘快速檢測套組市場（依樣本類型分類）

  • 病灶拭子
    • 水痘液
    • 焦痂物質
  • 口咽拭子
  • 鼻咽拭子
  • 唾液
  • 全血
    • 指尖採血（微血管）
    • 靜脈血採樣
  • 血清或血漿

第10章 猴痘快速檢測套組市場（依分銷通路分類）

  • 直接機構銷售
  • 集團採購組織協議
  • 批發商和經銷商
  • 零售藥房
  • 網路藥房
  • 電子商務市場
  • 非營利組織和捐助者資助的採購

第11章 猴痘快速檢測套組市場（依應用領域分類）

  • 臨床診斷
  • 篩檢和監測
    • 社區篩檢
    • 高風險族群篩檢
    • 旅行和邊境篩檢
  • 疫情管理
    • 確診病例
    • 接觸者追蹤支持
  • 研究用途

第12章 猴痘快速檢測套組市場（依最終用戶分類）

  • 醫院
    • 公立醫院
    • 私立醫院
  • 診所
    • 基層醫療診所
    • 性健康與皮膚病診所
  • 診斷實驗室
    • 獨立參考實驗室
    • 公共衛生實驗室
  • 門診手術中心
  • 藥局
  • 職業健康服務提供者
  • 非政府組織
  • 研究和學術機構

第13章 猴痘快速檢測套組市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 猴痘快速檢測套組市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國猴痘快速檢測套組市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國快速猴痘檢測套組市場

第17章：中國猴痘快速檢測套組市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • ACON BIoTech Co., Ltd.
  • Altona Diagnostics GmbH
  • Becton, Dickinson and Company
  • Beijing Hotgen BIoTech Co., Ltd.
  • BGI Group
  • BioChain Science-Technology, Inc.
  • Bioperfectus Technologies Co., Ltd.
  • DaAn Gene Co., Ltd.
  • Guangzhou Wondfo BIoTech Co., Ltd.
  • Joysbio BIoTechnology Co., Ltd.
  • Novacyt SA
  • Revvity, Inc.
  • Roche Diagnostics
  • Sansure BIoTech Inc.
  • Shanghai ZJ Bio-Tech Co., Ltd.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trivitron Healthcare Pvt. Ltd.
  • Zhejiang Orient Gene BIoTech Co., Ltd.
Product Code: MRR-0A3806951860

The Monkeypox Rapid Test Kit Market was valued at USD 439.37 million in 2025 and is projected to grow to USD 476.56 million in 2026, with a CAGR of 7.33%, reaching USD 721.05 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 439.37 million
Estimated Year [2026] USD 476.56 million
Forecast Year [2032] USD 721.05 million
CAGR (%) 7.33%

A strategic primer explaining why rapid monkeypox diagnostics have become essential tools in clinical workflows, public health response, and supply chain planning

Rapid diagnostics have moved from niche laboratory tools to frontline instruments in outbreak containment and clinical triage. The advent of sensitive, point-of-care assays for orthopoxviruses has shifted clinical pathways, enabling earlier case identification, more timely isolation protocols, and improved allocation of public health resources. This introduction outlines the operational imperatives driving demand for monkeypox rapid test kits and situates the product category within broader infectious disease preparedness frameworks.

Clinicians and public health decision-makers now expect assays that balance analytical performance with usability, supply chain reliability, and fast turnaround. Consequently, manufacturers are under pressure to streamline production, adhere to evolving regulatory expectations, and demonstrate robustness across real-world settings. The need for pragmatic test designs that perform reliably in clinics, diagnostic laboratories, home care environments, and hospitals has become paramount, and this report frames the technical, regulatory, and adoption dynamics influencing product evolution.

Finally, the introduction underscores how diagnostic innovation intersects with policy, procurement, and community-level programs. Stakeholders must navigate trade-offs between sensitivity, ease of use, and distribution logistics, while ensuring that rapid diagnostics complement molecular reference testing and surveillance systems. This section establishes the baseline context for deeper analysis of technological shifts, tariff implications, segmentation patterns, regional dynamics, and actionable recommendations.

How technological refinement, decentralization of care, and strengthened regulatory expectations are redefining rapid monkeypox diagnostic strategies and market behavior

The landscape for rapid monkeypox diagnostics is undergoing transformative shifts driven by technological maturation, shifting care models, and evolving regulatory expectations. First, point-of-care platforms that once targeted limited use cases are now being engineered for broader clinical and community contexts; usability, shelf stability, and minimal operator training have become design imperatives. As a result, lateral flow formats and microfluidic platforms are adapting to deliver more consistent performance while preserving affordability and scalability.

Second, an increased emphasis on decentralized testing is reshaping distribution and procurement strategies. Healthcare networks and community programs are integrating rapid tests into screening algorithms that prioritize rapid isolation and contact tracing. This decentralization is complemented by a surge in consumer- and community-facing offerings designed for home care settings and supported by telehealth linkages that enable remote triage and reporting. Consequently, interoperability with digital reporting systems and clear instructions for patient self-testing are now critical value propositions.

Third, regulatory pathways and quality assurance practices are converging on standards that emphasize clinical validation across diverse populations and settings. Manufacturers are investing in robust clinical evidence and post-market surveillance to support wider adoption. These concurrent shifts-technological refinement, decentralization of care, and stronger regulatory frameworks-collectively accelerate adoption and necessitate strategic adaptation among manufacturers, distributors, and health system purchasers.

The cumulative effects of tariff-driven supply chain pressures in 2025 and the strategic responses that recalibrated procurement, manufacturing, and distribution decisions

The imposition of new tariffs and trade measures in 2025 introduced a fresh layer of complexity into global supply chains for diagnostic components and finished rapid test kits. Suppliers that previously relied on low-cost manufacturing hubs faced immediate cost pressures that prompted a reassessment of sourcing, inventory strategies, and contractual terms. Many manufacturers sought to mitigate exposure through diversification of suppliers, nearshoring of critical processes, and renegotiated terms with contract manufacturers.

Consequently, procurement teams and distributors revised purchasing strategies to emphasize supply resilience over lowest-cost bidding. This pivot favored suppliers with geographically distributed manufacturing footprints or those that had already invested in regional assembly capabilities. Meanwhile, downstream stakeholders such as hospitals and laboratories began re-evaluating inventory buffers and contingency plans to account for potential disruptions stemming from tariff-driven lead-time variability.

On the other hand, some manufacturers accelerated automation investments and process optimizations to absorb increased input costs without transferring the full burden to customers. Strategic partnerships between component suppliers and kit assemblers emerged as a practical response, enabling joint investments in logistics and capacity planning. Collectively, these adaptations have reshaped competitive dynamics, with procurement decision-making now placing greater weight on supply chain transparency, regulatory compliance, and long-term reliability alongside unit economics.

In-depth segmentation analysis linking product immunoassay types, platform technologies, care settings, and distribution pathways to adoption dynamics and commercial strategy

Segmentation insights reveal how product design, platform choice, clinical use setting, and channel strategy intersect to determine adoption pathways for rapid monkeypox diagnostics. Based on product type, distinctions among IgG, IgG/IgM combined, and IgM assays are shaping clinical utility: IgM-focused tests prioritize early infection detection and are favored in acute diagnostic pathways, while IgG and combined formats support serostatus assessment and retrospective case investigations. These functional differences guide where and how tests are deployed, influencing manufacturer focus on analytical sensitivity, cross-reactivity profiles, and timing of specimen collection.

Turning to test technology, differences among colloidal gold immunochromatographic assays, lateral flow immunoassays, and microfluidic platforms create divergent trade-offs between cost, ease of interpretation, and quantitative capability. Within lateral flow immunoassays, cassette and strip formats cater to distinct user needs: cassette formats often provide a more robust, user-friendly housing for point-of-care settings, whereas strip formats deliver cost and packaging efficiencies that suit high-volume screening applications. Microfluidic platforms are gaining attention for their ability to integrate sample processing with multiplexing potential, appealing to diagnostic laboratories and specialty clinics that demand higher analytic rigor.

End user segmentation further clarifies adoption dynamics across clinics, diagnostic laboratories, home care settings, and hospitals. Diagnostic laboratories bifurcate into hospital laboratories and independent laboratories, each with unique procurement cycles and throughput requirements; hospital laboratories typically integrate rapid tests into broader diagnostic algorithms, while independent laboratories emphasize cost-efficiency and batch processing. Home care settings consist of community health programs and patient self-testing; community programs prioritize ease of use and training materials, whereas patient self-testing demands intuitive instructions, clear result interpretation, and pathways for reporting. Hospitals divide into general hospitals and specialty hospitals, with general hospitals seeking versatile point-of-care tools and specialty hospitals requiring tests validated for specific clinical cohorts.

Finally, distribution channel segmentation-direct tender, hospital pharmacies, online sales, and retail pharmacies-shapes accessibility and commercial strategy. Online sales split into B2B portals and B2C platforms, enabling both institutional procurement and patient-directed acquisition, while retail pharmacies separate into chain pharmacies and independent pharmacies, each offering distinct shelf-space dynamics, promotional opportunities, and customer engagement models. Taken together, these layered segments define where investment in product design, regulatory evidence, and go-to-market resources will deliver the greatest impact.

How regional healthcare infrastructures, regulatory priorities, and distribution ecosystems across the Americas, Europe, Middle East & Africa, and Asia-Pacific determine deployment strategies for rapid diagnostics

Regional dynamics reflect distinct healthcare infrastructures, regulatory frameworks, and distribution ecosystems across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each presenting specific operational considerations for rapid test deployment. In the Americas, integration of rapid diagnostics into emergency response and community screening programs has been supported by strong laboratory networks and established supply chains, yet disparities in rural access and reimbursement pathways necessitate targeted distribution strategies that emphasize both hospital and retail pharmacy channels.

Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization efforts coexist with variable procurement capacities. In some countries, centralized public health purchasing offers scale advantages, while other markets require localized engagement with hospital networks and diagnostic laboratories. Regulatory emphasis on clinical validation and post-market performance has elevated the importance of robust evidence packages and interoperability with surveillance reporting systems.

Asia-Pacific includes diverse markets ranging from advanced urban centers with sophisticated laboratory infrastructures to regions where community health initiatives are the primary mechanism for outreach. Manufacturers that tailor packaging, training materials, and distribution models to local practices-such as aligning with community health programs or leveraging chain pharmacy networks-tend to achieve deeper market penetration. Across all regions, digital reporting integration and culturally appropriate patient-facing guidance enhance uptake and trust in rapid diagnostics.

Transitioning between regions requires adaptive regulatory strategies, nuanced channel partnerships, and a keen understanding of payer models and public health priorities. These regional differences underscore the need for modular product designs and flexible commercial approaches that can be localized efficiently.

Competitive landscape dynamics revealing how clinical validation, strategic partnerships, and service integration differentiate companies in the rapid diagnostic ecosystem

Competitive dynamics in the rapid monkeypox diagnostics space are shaped by a mix of established in vitro diagnostics firms, specialized rapid-test manufacturers, and agile emerging entrants. Key companies differentiate on the basis of platform versatility, regulatory track record, and the strength of distribution networks. Firms that invest in clinical validation across diverse settings and that can demonstrate consistent lot-to-lot performance tend to secure preferred relationships with hospitals and centralized procurement bodies.

Strategic alliances between component suppliers, contract manufacturers, and commercial distributors have become common, enabling companies to scale production while navigating tariff-related cost pressures and logistics constraints. Additionally, firms that offer integrated services-such as training materials, digital result capture, and reporting capabilities-gain competitive advantage by lowering adoption friction for end users. Partnerships with clinical laboratories for real-world performance studies and post-market surveillance reinforce credibility with regulators and purchasers.

New entrants are influencing product design by prioritizing ease of use, smaller footprints, and user-centric packaging that supports patient self-testing and community deployment. Meanwhile, established players leverage existing relationships with hospital pharmacies and procurement departments to maintain market access. These dynamics create a bifurcated landscape: innovation-driven niche providers push technical boundaries, while larger firms emphasize scale, reliability, and compliance as differentiators in institutional channels.

Actionable strategic priorities for manufacturers and distributors to align product design, resilient supply chains, and evidence generation with regional channel strategies

Industry leaders should pursue a coordinated strategy that aligns product design, supply chain resilience, and evidence generation to accelerate adoption and sustain competitive advantage. First, prioritize platform adaptability by offering test formats that accommodate both point-of-care workflows and centralized laboratory confirmation. Designing assays that facilitate both clinical and community use will expand addressable use cases and simplify procurement conversations across diverse end users.

Second, strengthen supply chain resilience through supplier diversification, regional assembly options, and transparent inventory visibility. Building dual-source components and establishing contingency inventory buffers will reduce exposure to tariff-driven volatility and enable steadier fulfillment for tenders and hospital contracts. Simultaneously, invest in automation and process optimization to contain unit costs while maintaining quality.

Third, commit to rigorous, context-specific clinical validation and post-market surveillance. Evidence that demonstrates performance across intended user settings-such as hospital laboratories, independent labs, clinics, community health programs, and patient self-testing-will improve buyer confidence and regulatory acceptance. Complement these efforts with accessible training, digital result-capture tools, and clear reporting pathways to streamline adoption.

Finally, tailor commercial strategies by aligning channel tactics with regional nuances: engage hospital pharmacies and tender processes in institutional markets, while leveraging online B2B portals, B2C platforms, and retail pharmacy partnerships to reach decentralized and consumer-facing segments. By integrating these strategic priorities, leaders can translate technical advantages into durable market positions.

A transparent and reproducible multi-method research approach combining stakeholder interviews, regulatory review, and supply chain scenario analysis to underpin the report's conclusions

This research synthesized primary qualitative interviews, secondary literature review, and a systematic mapping of regulatory and distribution frameworks to build a comprehensive view of the rapid diagnostic landscape. Primary inputs included structured interviews with clinicians, laboratory directors, hospital procurement officers, community health program managers, and senior executives involved in diagnostic commercialization. Interview findings were triangulated with regulatory documents, peer-reviewed clinical validation studies, and publicly available post-market performance summaries to ensure alignment with current practice.

Analytical methods emphasized comparative case analysis across different platform types and end-user settings. The study evaluated usability attributes, turnaround time considerations, and integration requirements for reporting and surveillance. Supply chain assessment employed scenario analysis to model the operational impact of tariff shifts and component sourcing disruptions, focusing on practical mitigation strategies adopted by manufacturers and distributors.

Quality assurance included cross-validation of interview insights against regulatory filings and laboratory evaluation reports where available. Where gaps existed, conservative interpretation guided framing of implications rather than quantitative projections. The methodology prioritized transparency and reproducibility, documenting data sources, interview protocols, and analytic assumptions to enable stakeholders to assess applicability to their specific operational environments.

A concise synthesis of diagnostic, supply chain, and regional dynamics that defines strategic imperatives for stakeholders operating in the rapid monkeypox testing environment

In summary, the rapid monkeypox diagnostic landscape is characterized by accelerating decentralization of testing, technological differentiation across platform types, and heightened emphasis on supply chain resilience in the face of trade-driven pressures. Distinct product types-IgM, IgG, and combined assays-serve complementary clinical roles, while platform choices such as lateral flow, colloidal gold, and microfluidic systems define trade-offs between cost, ease of use, and analytical capability. End users ranging from hospital laboratories to patient self-testing channels demand tailored solutions and evidence that demonstrates real-world performance.

Regional nuances underscore the need for adaptable regulatory strategies and localization of distribution models. Competitive advantage accrues to companies that combine rigorous clinical validation with robust logistics and integrated services that lower adoption friction. Taken together, these dynamics create clear opportunities for stakeholders to innovate in product design, strengthen supply chain arrangements, and refine commercial approaches to meet the evolving needs of clinicians, patients, and public health systems.

Moving forward, decision-makers should treat diagnostics as strategic assets within outbreak preparedness and routine clinical care, ensuring that investments in quality, accessibility, and interoperability align with broader public health objectives and institutional procurement priorities.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Monkeypox Rapid Test Kit Market, by Test Technology

  • 8.1. Lateral Flow Immunoassay
    • 8.1.1. Visual Read
    • 8.1.2. Reader-based
  • 8.2. Isothermal Nucleic Acid Amplification
    • 8.2.1. Loop-mediated Amplification
    • 8.2.2. Recombinase Polymerase Amplification
  • 8.3. Rapid Polymerase Chain Reaction
    • 8.3.1. Cartridge-based System
    • 8.3.2. Open System Kit
  • 8.4. CRISPR-based Detection
    • 8.4.1. Cas12 Assay
    • 8.4.2. Cas13 Assay

9. Monkeypox Rapid Test Kit Market, by Sample Type

  • 9.1. Lesion Swab
    • 9.1.1. Vesicle Fluid
    • 9.1.2. Crust Material
  • 9.2. Oropharyngeal Swab
  • 9.3. Nasopharyngeal Swab
  • 9.4. Saliva
  • 9.5. Whole Blood
    • 9.5.1. Fingerstick Capillary
    • 9.5.2. Venous Draw
  • 9.6. Serum or Plasma

10. Monkeypox Rapid Test Kit Market, by Distribution Channel

  • 10.1. Direct Institutional Sales
  • 10.2. Group Purchasing Organization Contracts
  • 10.3. Wholesalers and Distributors
  • 10.4. Retail Pharmacies
  • 10.5. Online Pharmacies
  • 10.6. E-commerce Marketplaces
  • 10.7. Non-profit and Donor-funded Procurement

11. Monkeypox Rapid Test Kit Market, by Application

  • 11.1. Clinical Diagnosis
  • 11.2. Screening and Surveillance
    • 11.2.1. Community Screening
    • 11.2.2. High-risk Population Screening
    • 11.2.3. Travel and Border Screening
  • 11.3. Outbreak Management
    • 11.3.1. Case Confirmation
    • 11.3.2. Contact Tracing Support
  • 11.4. Research Use

12. Monkeypox Rapid Test Kit Market, by End User

  • 12.1. Hospitals
    • 12.1.1. Public Hospitals
    • 12.1.2. Private Hospitals
  • 12.2. Clinics
    • 12.2.1. Primary Care Clinics
    • 12.2.2. Sexual Health and Dermatology Clinics
  • 12.3. Diagnostic Laboratories
    • 12.3.1. Independent Reference Laboratories
    • 12.3.2. Public Health Laboratories
  • 12.4. Ambulatory Surgical Centers
  • 12.5. Pharmacies
  • 12.6. Occupational Health Providers
  • 12.7. Non-governmental Organizations
  • 12.8. Research and Academic Institutes

13. Monkeypox Rapid Test Kit Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Monkeypox Rapid Test Kit Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Monkeypox Rapid Test Kit Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Monkeypox Rapid Test Kit Market

17. China Monkeypox Rapid Test Kit Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. ACON Biotech Co., Ltd.
  • 18.7. Altona Diagnostics GmbH
  • 18.8. Becton, Dickinson and Company
  • 18.9. Beijing Hotgen Biotech Co., Ltd.
  • 18.10. BGI Group
  • 18.11. BioChain Science-Technology, Inc.
  • 18.12. Bioperfectus Technologies Co., Ltd.
  • 18.13. DaAn Gene Co., Ltd.
  • 18.14. Guangzhou Wondfo Biotech Co., Ltd.
  • 18.15. Joysbio Biotechnology Co., Ltd.
  • 18.16. Novacyt S.A.
  • 18.17. Revvity, Inc.
  • 18.18. Roche Diagnostics
  • 18.19. Sansure Biotech Inc.
  • 18.20. Shanghai ZJ Bio-Tech Co., Ltd.
  • 18.21. Siemens Healthineers AG
  • 18.22. Thermo Fisher Scientific Inc.
  • 18.23. Trivitron Healthcare Pvt. Ltd.
  • 18.24. Zhejiang Orient Gene Biotech Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MONKEYPOX RAPID TEST KIT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY TEST TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES MONKEYPOX RAPID TEST KIT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA MONKEYPOX RAPID TEST KIT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY VISUAL READ, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY VISUAL READ, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY VISUAL READ, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY READER-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY READER-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY READER-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY LOOP-MEDIATED AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY LOOP-MEDIATED AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY LOOP-MEDIATED AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY RECOMBINASE POLYMERASE AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY RECOMBINASE POLYMERASE AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY RECOMBINASE POLYMERASE AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY RAPID POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY RAPID POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY RAPID POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY RAPID POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CARTRIDGE-BASED SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CARTRIDGE-BASED SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CARTRIDGE-BASED SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY OPEN SYSTEM KIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY OPEN SYSTEM KIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY OPEN SYSTEM KIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CRISPR-BASED DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CRISPR-BASED DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CRISPR-BASED DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CRISPR-BASED DETECTION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CAS12 ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CAS12 ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CAS12 ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CAS13 ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CAS13 ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CAS13 ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY LESION SWAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY LESION SWAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY LESION SWAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY LESION SWAB, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY VESICLE FLUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY VESICLE FLUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY VESICLE FLUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CRUST MATERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CRUST MATERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CRUST MATERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY OROPHARYNGEAL SWAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY OROPHARYNGEAL SWAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY OROPHARYNGEAL SWAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY WHOLE BLOOD, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY FINGERSTICK CAPILLARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY FINGERSTICK CAPILLARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY FINGERSTICK CAPILLARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY VENOUS DRAW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY VENOUS DRAW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY VENOUS DRAW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY SERUM OR PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY SERUM OR PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY SERUM OR PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY DIRECT INSTITUTIONAL SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY DIRECT INSTITUTIONAL SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY DIRECT INSTITUTIONAL SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY GROUP PURCHASING ORGANIZATION CONTRACTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY GROUP PURCHASING ORGANIZATION CONTRACTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY GROUP PURCHASING ORGANIZATION CONTRACTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY WHOLESALERS AND DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY WHOLESALERS AND DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY WHOLESALERS AND DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY E-COMMERCE MARKETPLACES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY E-COMMERCE MARKETPLACES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY E-COMMERCE MARKETPLACES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY NON-PROFIT AND DONOR-FUNDED PROCUREMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY NON-PROFIT AND DONOR-FUNDED PROCUREMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY NON-PROFIT AND DONOR-FUNDED PROCUREMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CLINICAL DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CLINICAL DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CLINICAL DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY SCREENING AND SURVEILLANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY SCREENING AND SURVEILLANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY SCREENING AND SURVEILLANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY SCREENING AND SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY COMMUNITY SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY COMMUNITY SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY COMMUNITY SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY HIGH-RISK POPULATION SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY HIGH-RISK POPULATION SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY HIGH-RISK POPULATION SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY TRAVEL AND BORDER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY TRAVEL AND BORDER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY TRAVEL AND BORDER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY OUTBREAK MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY OUTBREAK MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY OUTBREAK MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY OUTBREAK MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CASE CONFIRMATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CASE CONFIRMATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CASE CONFIRMATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CONTACT TRACING SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CONTACT TRACING SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CONTACT TRACING SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY RESEARCH USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY RESEARCH USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY RESEARCH USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY PRIMARY CARE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY PRIMARY CARE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY SEXUAL HEALTH AND DERMATOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY SEXUAL HEALTH AND DERMATOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY SEXUAL HEALTH AND DERMATOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY INDEPENDENT REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY INDEPENDENT REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY INDEPENDENT REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY PUBLIC HEALTH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY PUBLIC HEALTH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY PUBLIC HEALTH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY OCCUPATIONAL HEALTH PROVIDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY OCCUPATIONAL HEALTH PROVIDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY OCCUPATIONAL HEALTH PROVIDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY NON-GOVERNMENTAL ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY NON-GOVERNMENTAL ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY NON-GOVERNMENTAL ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL MONKEYPOX RAPID TEST KIT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS MONKEYPOX RAPID TEST KIT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS MONKEYPOX RAPID TEST KIT MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS MONKEYPOX RAPID TEST KIT MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS MONKEYPOX RAPID TEST KIT MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS MONKEYPOX RAPID TEST KIT MARKET SIZE, BY RAPID POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CRISPR-BASED DETECTION, 2018-2032 (USD MILLION)
  • TABLE 181. AMERICAS MONKEYPOX RAPID TEST KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. AMERICAS MONKEYPOX RAPID TEST KIT MARKET SIZE, BY LESION SWAB, 2018-2032 (USD MILLION)
  • TABLE 183. AMERICAS MONKEYPOX RAPID TEST KIT MARKET SIZE, BY WHOLE BLOOD, 2018-2032 (USD MILLION)
  • TABLE 184. AMERICAS MONKEYPOX RAPID TEST KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. AMERICAS MONKEYPOX RAPID TEST KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. AMERICAS MONKEYPOX RAPID TEST KIT MARKET SIZE, BY SCREENING AND SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 187. AMERICAS MONKEYPOX RAPID TEST KIT MARKET SIZE, BY OUTBREAK MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 188. AMERICAS MONKEYPOX RAPID TEST KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. AMERICAS MONKEYPOX RAPID TEST KIT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 190. AMERICAS MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 191. AMERICAS MONKEYPOX RAPID TEST KIT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY RAPID POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CRISPR-BASED DETECTION, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY LESION SWAB, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY WHOLE BLOOD, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY SCREENING AND SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY OUTBREAK MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. NORTH AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY RAPID POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CRISPR-BASED DETECTION, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY LESION SWAB, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY WHOLE BLOOD, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY SCREENING AND SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY OUTBREAK MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY RAPID POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CRISPR-BASED DETECTION, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY LESION SWAB, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY WHOLE BLOOD, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY SCREENING AND SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY OUTBREAK MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE MONKEYPOX RAPID TEST KIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE MONKEYPOX RAPID TEST KIT MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE MONKEYPOX RAPID TEST KIT MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE MONKEYPOX RAPID TEST KIT MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE MONKEYPOX RAPID TEST KIT MARKET SIZE, BY RAPID POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CRISPR-BASED DETECTION, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE MONKEYPOX RAPID TEST KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE MONKEYPOX RAPID TEST KIT MARKET SIZE, BY LESION SWAB, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE MONKEYPOX RAPID TEST KIT MARKET SIZE, BY WHOLE BLOOD, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE MONKEYPOX RAPID TEST KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE MONKEYPOX RAPID TEST KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE MONKEYPOX RAPID TEST KIT MARKET SIZE, BY SCREENING AND SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE MONKEYPOX RAPID TEST KIT MARKET SIZE, BY OUTBREAK MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE MONKEYPOX RAPID TEST KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE MONKEYPOX RAPID TEST KIT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE MONKEYPOX RAPID TEST KIT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST MONKEYPOX RAPID TEST KIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST MONKEYPOX RAPID TEST KIT MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 262. MIDDLE EAST MONKEYPOX RAPID TEST KIT MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST MONKEYPOX RAPID TEST KIT MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST MONKEYPOX RAPID TEST KIT MARKET SIZE, BY RAPID POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CRISPR-BASED DETECTION, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST MONKEYPOX RAPID TEST KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST MONKEYPOX RAPID TEST KIT MARKET SIZE, BY LESION SWAB, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST MONKEYPOX RAPID TEST KIT MARKET SIZE, BY WHOLE BLOOD, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST MONKEYPOX RAPID TEST KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST MONKEYPOX RAPID TEST KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST MONKEYPOX RAPID TEST KIT MARKET SIZE, BY SCREENING AND SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 272. MIDDLE EAST MONKEYPOX RAPID TEST KIT MARKET SIZE, BY OUTBREAK MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST MONKEYPOX RAPID TEST KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. MIDDLE EAST MONKEYPOX RAPID TEST KIT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 276. MIDDLE EAST MONKEYPOX RAPID TEST KIT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 277. AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 278. AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 280. AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 281. AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY RAPID POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 282. AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CRISPR-BASED DETECTION, 2018-2032 (USD MILLION)
  • TABLE 283. AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY LESION SWAB, 2018-2032 (USD MILLION)
  • TABLE 285. AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY WHOLE BLOOD, 2018-2032 (USD MILLION)
  • TABLE 286. AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 287. AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 288. AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY SCREENING AND SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 289. AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY OUTBREAK MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 290. AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 292. AFRICA MONKEYPOX RAPID TEST KIT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)

TABLE 293.